臨床研究等提出・公開システム

Efficacy of emulsion with anti-Staphylococcus aureus ostrich antibody for atopic dermatitis (EASII Study)

EASII Study (EASII Study)

Miyagawa Fumi

Nara Medical University Hospital

840 Shijo-cho, Kashihara, Nara

fumim@naramed-u.ac.jp

Miyagawa Fumi

Nara Medical University Hospital

840 Shijo-cho, Kashihara, Nara

+81-744-22-3051

fumim@naramed-u.ac.jp

Not Recruiting

April. 18, 2024

Interventional

single arm study

single blind

placebo control

single assignment

treatment purpose

1) Patients with atopic dermatitis receiving therapy with dupilumab for 16 weeks
2) Patients who having treatment-resistant bisymmetric lesion evaluated the same grade severity (four categories: mild, moderate, severe, most severe) with Eczema Area and Severity Index (EASI) score in local lesion
3) Patients who are 18 years old and more at informed consent
4) Patients who is eligible to agree with consent form

1) Patients determined ineligible to participate by principal investigator or sub investigator

Both

Atopic Dermatitis

The anti-Staphylococcus aureus ostrich antibody emulsion will be put the target lesion over on the left side and placebo emulsion will be put the target lesion over on the right side, per two palms with 0.5g (2cm in diameter) twice daily (morning and evening, after bathing if possible) for 4 weeks.

Rates of change from baseline to 4 weeks after started the treatment at Eczema Area and Severity Index (EASI) score in local lesion

Rates of change from baseline to 2 weeks after started the treatment at EASI score in local lesion.
Points of change from baseline to 2 or 4 weeks after started the treatment at Numerical Rating Scale score.
Points of change from baseline to 2 or 4 weeks after started the treatment at The Patient Oriented Eczema Measure score.

+81-744-29-8835

Mar. 19, 2024

none